GlassScriptPhysician profile
Macresia A Braziel
NPI 1124493432
$2,768.23
in general payments reported to CMS, 2019-2025
27 companies · $95.85 in 2025
The $95.85 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $691 · 2022: $874 · 2023: $785 · 2024: $322 · 2025: $95.85.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,204.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,203.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $412.62 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $293.00 | 2021-2023 | Farxiga |
| Novo Nordisk INC | $234.13 | 2021-2024 | Wegovy, Ozempic |
| Mallinckrodt Hospital Products INC. | $196.42 | 2022-2023 | Acthar |
| Amgen INC. | $172.86 | 2021-2023 | Repatha, Otezla |
| Horizon Therapeutics Plc | $139.12 | 2022-2023 | Krystexxa |
| Alnylam Pharmaceuticals INC. | $126.38 | 2021-2023 | Oxlumo |
| Medtronic, INC. | $124.99 | 2021 | |
| Abbvie INC. | $124.99 | 2023 | |
| Gilead Sciences, INC. | $122.40 | 2024 | Biktarvy |
| Janssen Products, LP | $121.73 | 2023 | Symtuza |
| Janssen Pharmaceuticals, INC | $112.50 | 2021 | |
| Ani Pharmaceuticals, INC. | $79.99 | 2022-2023 | Purified Cortrophin Gel |
| Rhythm Pharmaceuticals, INC. | $74.60 | 2025 | Imcivree |
| Lilly USA, LLC | $71.57 | 2022-2023 | Mounjaro |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $70.04 | 2022-2023 | Tarpeyo |
| Otsuka America Pharmaceutical, INC. | $50.89 | 2022-2023 | Jynarque |
| Exact Sciences Corporation | $47.05 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Cranial Technologies, INC | $35.98 | 2024 | Doc Band |
| Fresenius USA Marketing, INC. | $23.42 | 2022 | |
| Amicus Therapeutics, INC. | $22.24 | 2021 | |
| Aurinia Pharma U.S., INC. | $21.53 | 2022 | |
| Merck Sharp & Dohme LLC | $19.89 | 2023 | |
| Vifor Pharma, INC. | $19.43 | 2023 | Korsuva |
| Genzyme Corporation | $17.45 | 2022 | |
| Pfizer INC. | $17.14 | 2024 | |
| Opko Pharmaceuticals, LLC | $15.87 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Macresia Braziel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.